Gilead (GILD) volatility elevated into less than expected Q1 results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Gilead Sciences (GILD) PT Lowered to $90 at RBC Capital
May 2, 2018 8:26 AM EDTRBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $94.00) while maintaining an Outperform rating following a disappointing quarter.
... More
Gilead Sciences (GILD) PT Lowered to $79 at Baird
May 2, 2018 7:51 AM EDTBaird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on weaker than expected 1Q.
Analyst Brian Skorney commented, "While investors had projected 2018 as a trough earnings year for the company, worse than expected sales... More
Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley
May 2, 2018 7:45 AM EDTMorgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.
1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More
